Precision for Medicine announced a strategic partnership with Sophia Genetics (SOPH) to enhance its biomarker discovery and precision medicine services. As part of this collaboration, Precision for Medicine will integrate the Sophia DDM Platform for biomarker discovery, clinical trial assays, and advanced algorithms to expand clinical trial capabilities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOPH:
- Sophia Genetics price target lowered to $5 from $6 at BTIG
- SOPHiA GENETICS: Strong Financial Performance and Strategic Positioning Drive Buy Rating
- SOPHiA GENETICS Reports 2024 Financial Results
- SOPHiA GENETICS Earnings Call: Mixed Results, Optimistic Outlook
- SOPHiA GENETICS Reports 2024 Financial Results and Sets Growth Path for 2025